Member Info for Cleanerworld

I agree heard more from Professor Christian Ottensmeier . Than Scancell. Who must be rather busy

Yes I agree. This is an enormous achievement. The value is unrealised and under valued .

many thanks

makes you wonder . I suspect you could be right ? any news on who bought Lindys shares ?

marcusl2: Scancell has developed a novel technology platform for producing mAbs that recognise glycans with high specificity and affinity. In the past this has been challenging as anti-glycan antibodies tend to have low affinity for their targets. However, Scancell is one of the few groups in the world to overcome this limitation and is now able to produce high-affinity anti-glycan mAbs with direct killing properties. Scancell has created a portfolio of anti-glycan mAbs that recognise and directly kill cancer cells without the need for involvement of the complement system or immune accessory cells. These mAbs also have the potential to be used for drug delivery (for example, as antibody drug conjugates: ADC), as chimeric antigen receptor (CAR) T cells or for redirected T cell killing. The GlyMab™ platform has the potential to generate many more mAbs against a wide range of tumour-associated glycoproteins and glycolipids. In a further refinement, Scancell has identified specific and precise antibody modifications that enhance the avidity of target recognition. This AvidiMab® technology has been used to increase the direct killing ability of Scancell’s own anti-glycan mAb portfolio but also has the potential to enhance the efficacy of other mAbs or antibody-based therapies currently in development or available commercially. AvidiMab could be used to enhance the avidity and potency of virtually any antibody-based product. It would also extend the patent life of commercially established programmes. Hence its appeal could be significant. HTTPS://www.scancell.co.uk/antibodies SC129: specific for the sialyl-di-Lewisa glycan, a target for pancreatic cancer SC134: specific for fucosyl GM1, a target for small cell lung cancer SC88: specific for the Lewisacx glycan, a target for colorectal cancer SC27: specific for the Lewisy glycan, a target for gastric cancer SC2811: specific for SSEA4 on human and mouse T cells with stem-like properties – a target for any solid tumour HTTPS://www.scancell.co.uk/anti-glycan-mab
Read Full ThreadFollow

https://www.england.nhs.uk/blog/international-clinical-trials-day-2022/

https://www.pharmaceutical-technology.com/news/merck-keytruda-ec-approval/

wondering where Crackin has gone , because once again I think news and an RNS that I think is on its way soon will. lift this share and we know how fast it can move !

does anyone have the data ?

Very interesting post thanks Marcus Www.Glymab.com ? Is Interesting

Typo “impressed “ should be important!

Hugely satisfied with the science and IP of Scancell , suspect they been rather too busy to focus on Scancell's Global marketing strategy . which will be most impressed once the Licensing takes place !

xxx

just found this on investopia on a time when there is no media :
KEY TAKEAWAYS
A quiet period is a set amount of time when a company's management and marketing teams cannot share opinions or additional information about the firm.
The purpose of the quiet period is to preserve objectivity and avoid the appearance of a company providing insider information to select investors.
With an IPO, the quiet period stretches from when a company files registration paperwork with U.S. regulators through the 40 days after the stock starts trading.
With publicly-traded companies, the quiet period refers to the four weeks before the end of the business quarter.
The JOBS Act created a class of companies—emerging growth companies—doing away with specific quiet periods, notably the 25-day research quiet period

I agree

I have posted this before but its most relevant
https://www.lji.org/news-events/news/post/investigating-cancer-drug-toxicity-leads-to-a-critical-discovery/

when the "scancell boat" comes it , we will all be off fishing in bigger boats ???? ( yes it was a S***ty post .

so may lives will be saved and I agree I think he is talking about the Scancell science , could someone have a look at the 2014 paper it mentions

lets get this board back on track :

https://inews.co.uk/news/science/cancer-treatment-revolution-immunotherapy-radiotherapy-cures-1622164
Views please

Unbelievabley sad . He is undoubtedly missed.

?? May he rest in peace . After such a distinguished career

anyone else want to do a google search linking team leader with Durrant to see what comes up ?

https://www.imm.ox.ac.uk/news/mrc-human-immunology-unit-group-leader-in-team-shortlisted-for-ps20m-cruk-grand-challenge-award

I think this team is still active with Team leader Prof Lindy Durrant